Halozyme Therapeutics | HALO - Operating Expenses


Halozyme Therapeutics reported $193.34M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 11.69B 6.9B Jun/2026
Baxter International USD 2.68B 3.36B Jun/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cytokinetics USD 207.8M 7.22M Jun/2026
DBV Technologies USD 47.9M 2.2M Mar/2026
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
MannKind USD 110.21M 690K Jun/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
United Therapeutics USD 6.4B 499.2M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025